| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,999,995 | 2 | 67 |
Sells | $292,776 | 1 | 33 |
| SEIDENBERG BETH C | director | 1 | $999,998 | 0 | $0 | $999,998 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 1 | $999,998 | 0 | $0 | $999,998 |
| Walker Karen Marie | Chief Technology Officer | 0 | $0 | 1 | $292,776 | $-292,776 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product …
Over the last 12 months, insiders at Kyverna Therapeutics, Inc. have bought $2M and sold $292,776 worth of Kyverna Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kyverna Therapeutics, Inc. have bought $11.01M and sold $292,776 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SEIDENBERG BETH C (director) — $999,998. Westlake BioPartners Opportunity Fund I, L.P. (10 percent owner) — $999,998.
The last purchase of 133,333 shares for transaction amount of $999,998 was made by Westlake BioPartners Opportunity Fund I, L.P. (10 percent owner) on 2025‑12‑18.
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 133,333 0.3262% | $7.50 | $999,998 | +16.71% | ||
| 2025-12-18 | SEIDENBERG BETH C | director | 133,333 0.3262% | $7.50 | $999,998 | +16.71% | ||
| 2025-12-15 | Sale | Walker Karen Marie | Chief Technology Officer | 23,998 0.0618% | $12.20 | $292,776 | -24.58% | |
| 2024-02-12 | GILEAD SCIENCES, INC. | 10 percent owner | 910,000 8.0369% | $22.00 | $20.02M | -75.24% |
| SEIDENBERG BETH C | director | 869317 1.4057% | $4.49M | 1 | 0 | |
| Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 869317 1.4057% | $4.49M | 1 | 0 | |
| GILEAD SCIENCES, INC. | 10 percent owner | 4126119 6.6719% | $21.29M | 1 | 0 | <0.0001% |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$104,171,521 | 16 | 20.21% | $275.53M | |
$10,399,379 | 13 | 13.60% | $302.03M |
| Increased Positions | 65 | +79.27% | 18M | +79.64% |
| Decreased Positions | 34 | -41.46% | 2M | -10.14% |
| New Positions | 36 | New | 15M | New |
| Sold Out Positions | 11 | Sold Out | 1M | Sold Out |
| Total Postitions | 113 | +37.8% | 39M | +69.5% |
| Vida Ventures Advisors, Llc | $39,675.00 | 7.94% | 4.52M | 0 | 0% | 2025-09-30 |
| Gilead Sciences, Inc. | $36,186.00 | 7.24% | 4.13M | 0 | 0% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $29,541.00 | 5.91% | 3.37M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $13,262.00 | 2.65% | 1.51M | -318,302 | -17.39% | 2025-09-30 |
| Vanguard Group Inc | $11,599.00 | 2.32% | 1.32M | +9,858 | +0.75% | 2025-09-30 |
| Insight Holdings Group, Llc | $8,674.00 | 1.74% | 989,054 | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $5,942.00 | 1.19% | 677,587 | -17,440 | -2.51% | 2025-09-30 |
| Mbb Public Markets I Llc | $5,389.00 | 1.08% | 614,477 | 0 | 0% | 2025-09-30 |
| Catalio Capital Management, Lp | $5,147.00 | 1.03% | 586,909 | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,838.00 | 0.97% | 551,635 | +99,075 | +21.89% | 2025-09-30 |